EP0586553A1 - Derives de carboxamido-(3,2n)-2-aminotetralinecarbocyclique - Google Patents

Derives de carboxamido-(3,2n)-2-aminotetralinecarbocyclique

Info

Publication number
EP0586553A1
EP0586553A1 EP92912819A EP92912819A EP0586553A1 EP 0586553 A1 EP0586553 A1 EP 0586553A1 EP 92912819 A EP92912819 A EP 92912819A EP 92912819 A EP92912819 A EP 92912819A EP 0586553 A1 EP0586553 A1 EP 0586553A1
Authority
EP
European Patent Office
Prior art keywords
compounds
dopamine
carboxamido
propyl
hexahydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP92912819A
Other languages
German (de)
English (en)
Inventor
Chiu-Hong Lin
Montford E. Piercey
Susanne R. Haadsma-Svensson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of EP0586553A1 publication Critical patent/EP0586553A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Definitions

  • the present invention is related to new carboxamido-(3 ,2N)-carbocyclic-2-amino- 1,2,3,4-tetrahydronaphthylene derivatives, to processes for preparing such compounds, pharmaceutical preparation of such compounds and the use of such compounds in manufacture of a pharmaceutical preparation.
  • Psychiatric diseases are thought to be due to dysfunctions in monoaminergic neuronal systems, particularly those involving serotonin (5-HT) and dopamine (DA).
  • Schizophrenia is thought to be due to hyperactivity in DA systems.
  • DA antagonists Dopamine autoreceptors depress DA neuron firing rates, DA synthesis and release.
  • DA autoreceptor agonists can also be expected to be anti-psychotics.
  • DA agonists are also useful for treating Parldnsonism, a disease caused by degeneration of DA neurons, and hyperprolactinemia, since DA agonists depress prolactin release.
  • Dopamine autoreceptor antagonists are a new class of drug that increase release of DA by releasing the DA neuron from autoreceptor control. Thus, these drugs can be expected to be useful in conditions treatable with amphetamine and other similar stimulants which directly release DA. However, because DA autoreceptor agonists will be much milder stimulants because, rather than directly releasing DA, they simply increase the release associated with the normal DA activity by releasing the cell from autoreceptor control. Thus, DA autoreceptor antagonists can be expected to be useful in treating overeating, attention deficit disorders, psychiatric, cognitive and motor retardation in demented and elderly patients, and in treating nausea and dizziness with space travel.
  • the compounds of the present invention have a variety of effects at the DA receptors, and offer a variety of utilities associated with those activities.
  • Drugs acting on central dopamine transmission are clinically effective in treating a variety of central nervous system disorders such as parldnsonism, schizophrenia, and manic-depressive illness.
  • parldnsonism for example, the nigro-neostriatal hypofunction can be restored by an increase in postsynaptic dopamine receptor stimulation.
  • schizophrenia the condition can be normalized by achieving a decrease in postsynaptic dopamine receptor stimulation.
  • Classical anti-psychotic agents directly block the postsynaptic dopamine receptor. The same effect can be achieved by inhibition of intraneuronal presynaptic events essential for the maintenance of adequate neuro- transmission, transport mechanism and transmitter synthesis.
  • Direct dopamine receptor agonists like apomoiphine, are able to activate the dopamine autoreceptors as well as the post synaptic dopamine receptors.
  • the effects of autoreceptor stimulation appear to predominate when apomoiphine is administered at low doses, whereas at higher doses the attenuation of dopamine transmission is outweighed by the enhancement of postsynaptic receptor stimulation.
  • the anti-psychotic and anti- dyskinetic effects in man of low doses of apomoiphine are likely due to the autoreceptorstimulator properties of this dopamine receptor agonist. This body of knowledge indicates dopamine receptor stimulants with a high selectivity for central nervous dopamine autoreceptors would be valuable in treating psychiatric disorders.
  • 5-HT receptor agonist devoid of dopamine receptor stimulating activity.
  • the amine can be a mono or di substituted with simple alkyl groups, benzyl groups alkylalkoxy groups or the amine can be a 5 or 6 membered hydrocarbon or heterocyclic amine. These compounds are indicated to have dopaminergic properties although certain compounds are reported to be inactive.
  • Rusterholz, et al., J. Med. Chem., 19, 99 (1976) describes 5,8 disubstituted-2-aminotetralins with the amine being substituted with hydrogen, methyl, or cyanopropyl groups. Some of these compounds are potent prolactin inhibitors and believed to be dopamine agonists.
  • German Patent DE-A1-2 803 582 describes 2-aminotetralins where the aromatic ring is substituted on the 5,6,7 or 8 position a group R 1 , where R 1 is hydrogen, alkanoyl having 1 to 20 carbon atoms or a group -CO-(CH 2 ) n -R7, n is a number 0 to 5, R 7 is a phenyl group with substituents as defined further, R 2 is hydrogen, hydroxy, halogen or alkylsulfonylamino, R 3 is hydrogen, R 4 is hydrogen, CH 2 OH, CH 2 O-CO-R 8 or CH 2 -O-CO-(CH 2 ) n -R 7 with further definition and R 5 and R 6 are hydrogen, alkyl or aryl or aralkyl groups further defined or R 5 and R 6 are together an alkylene with 4 to 6 carbon atoms.
  • R 1 is hydrogen, alkanoyl having 1 to 20 carbon atoms or a group -CO-(CH 2
  • the compounds are disclosed as having pharmacodynamic activity in particular a stimulating effect on alpha-and beta-adrenoceptors and dopamine receptors.
  • the compounds described are compounds having the group R 10 in the 8 position and having R 2 or R 4 other than hydrogen.
  • 29348D/17 and 06733V/05 refer to 8-carboxyamino tetralins. Additional 07833V/05 refers to 8-amido and 8-alkylamido tetralin.
  • EPO patent application EPO 270947 (1988) discloses 8-hydroxy and 8-methoxy- tetralins.
  • 86-298374/45 discloses tetra-hydro-benzo-isindoline derivatives which interact specifically with various androgenic receptors and are useful for treating hypertension. 86-298374/45 also discloses that the compounds also have sedative activity.
  • U.S. Patent 4,622,405 discloses 1,2,3,3 ⁇ ,8,8 ⁇ -hexahydro indero(1,2-C)pyrroles(s).
  • Derwent 67323W/41 discloses benzoisoindolines as anti-aggressive and analgesic agents.
  • This invention encompasses compounds of Formula I, wherein R is C 1 -C 8 alkyl and n is 1 or 2.
  • the compounds of this invention possess selective pharmacological properties and are useful in treating central nervous system disorders including schizophrenia, Parkinson's disease, anxiety and depression.
  • Preferred compounds for treating schizophrenia and Parkinson's disease are those wherein the carboxamide group is in the 5, 6 or 7 position.
  • Particularly preferred compounds are those wherein the carboxamide group is in the 5 position.
  • the compounds of this invention are also useful in treating hypertension, congestive heart failure and cardiac arrythmias. Processes for preparation of these compounds, their pharmaceutical use and pharmaceutical preparations employing such compounds constitute further aspects of the invention.
  • An object of the invention is to provide compounds for therapeutic use, especially compounds having a therapeutic activity in the central nervous system.
  • a further object of this invention is to provide compounds having an effect on the subclass of dopamine receptors known as the D 2 receptor.
  • the compounds of this invention have been found to have unexpectedly superior resistance to liver metabolism and have excellent oral plasma bioavailability.
  • the compounds of this invention are identified in two ways: by the descriptive name and reference to labelled structures contained in appropriate charts. In appropriate situations, the proper stereochemistry is also represented in the charts.
  • alkyl refers to an aliphatic hydrocarbon radical and includes branched or unbranched forms such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, n-pentyl, isopentyl, neo-pentyl, n-hexyl, isohexyl, n-heptyl, isoheptyl, and n-octyl.
  • LDA is lithium diisopropyl amide.
  • compounds of this invention may contain chiral centers.
  • the scope of this invention includes all enantiomeric or diastereomeric forms of Formula I compounds either in pure form or as mixtures of enantiomers or diastereomers.
  • the compounds of Formula I contain two asymmetric carbon atoms in the aliphatic ring moiety, including the ring carbon atoms adjacent to the nitrogen atom.
  • the therapeutic properties of the compounds may to a greater or lesser degree depend on the stereochemistry of a particular compound. Pure enantiomers as well as enantiomeric or diastereomeric mixtures are within the scope of the invention.
  • the compounds of this invention may be obtained by one of the following methods described below and outlined in the appropriate charts.
  • the (3,2N) compounds can be made in accordance with the process illustrated in Chart A.
  • the methoxy derivative A-1 is resolved as described in prep 1.
  • the resolved A-1 is demethylated using diphenylphosphine and n-butyl lithium in THF to yield the hydroxy derivative A-2.
  • a process for the preparation of 2,3,3a,4,9,91-hexahydro-5-methoxy-1-n-propyl-1H-benz[f]indole is described in Example 4 and Chart E of application PCT/US90/03551 filed June 27, 1990 and published January 24, 1991.
  • step 2 the hydroxy derivative A-2 is reacted with trifluoromethanesulfonic anhydride in the presence of pyridine and methylene chloride to provide the triflate A-3.
  • step 3 the triflate A-3 is then reacted with palladium acetate and 1,3- bis(diphenylphosphino)propane in methanol/ dimethylformamide in the presence of gaseous carbon monoxide to yield the methyl ester A-4.
  • step 4 A-4 is first hydrolyzed to the carboxylic acid which is coupled with gaseous ammonia in the presence of diethylcyanophosphonate and triethylamine in dimethylformamide to give the carboxamido derivative A-5.
  • the compounds of the present invention will normally be administered orally, rectally, or by injection, in the form of pharmaceutical preparations comprising the active ingredient either as a free base or as a pharmaceutically acceptable non-toxic, acid addition salt in association with a pharmaceutically acceptable carrier.
  • organic and inorganic acids can be employed to form non-toxic pharmaceutically acceptable acid addition salts of the compounds of this invention.
  • Illustrative acids are sulfuric, nitric, phosphoric, hydrochloric, citric, acetic, lactic, tartaric, palmoic, ethanedisulfonic, sulfamic, succinic, cyclohexylsulfamic, fumaric, maleic, and benzoic acid. These salts are readily prepared by methods known in the art.
  • the suitable daily doses of the compounds of the invention are 0.1-2000 mg/kg for oral application, preferably 0.5-500 mg/kg, and 0.1-100 mg/kg for parenteral application, preferably 0.5-50 mg/kg.
  • the compounds of this invention wherein the carboxamide group is in the 5, 6 and 7 position in the aromatic ring have dopaminergic activity with little 5-HT 1A agonist activity. It has been found that the compounds of the present invention and pharmacologically acceptable salts thereof have unexpectedly superior resistance to liver metabolism and excellent oral plasma bioavailability. Generally aminotetralins agonist activity are rapidly metabolized by the liver and have poor oral plasma bioavailability. The excellent oral bioavailability of compounds contained in this invention results in good potency and long duration of action following oral administration of the compounds. Both these features are beneficial to effective clinical treatment.
  • the agent In order to be a dopaminergic agonist, the agent must bind to the dopamine receptor.
  • tissue high in dopamine receptors trans-(+)-2,3,3a,4,9,9a-Hexahydro—5-carboxamido-1-n-propyl-1H-benz[f]- indole [(-)A-5] dopamine receptors with an extremely high affinity (56 nM Table 1);
  • Dopaminergic agonists such as apomoiphine depress nerve impulses generated by dopaminergic neurons. Indeed, all full dopamine agonists can completely suppress impulse generation so that the dopamine cells stop firing completely. In contrast, dopamine antagonists either do not affect nerve impulse activity of dopamine neurons or increase them.
  • Trans-(+)-2,3,3a,4,9,9a-Hexahydro-5-carboxamido-1-n-propyl-1H-benz[f]indole [(-)A-5] was a very potent dopamine agonist, depressing dopamine nerve discharges by 50% with a dose of only 4 ug/kg i.v.
  • the HCl-salt of this material is recrystallized from ethyl acetate/methanol to give a white solid as a (-) enantiomer of A-1: mp. 263-265 °C, [ ⁇ ] D -140o (c 0.70, MeOH).
  • the mother liquor is free-based as described above and recrystallized from methanol using an appropriate amount (1.05 equivalents) of di-p-toluoyl-D-tartaric acid to give 11.6 g (42 %) of apure diastereomeric salt as a white solid after two recrystallizations.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des tetralines aux propriétés thérapeutiques et des sels d'addition acides pharmaceutiquement acceptables de ces tétralines de formule (I) où R est alkyle C1-C8 et n est 1 ou 2.
EP92912819A 1991-05-20 1992-03-11 Derives de carboxamido-(3,2n)-2-aminotetralinecarbocyclique Withdrawn EP0586553A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70281391A 1991-05-20 1991-05-20
US702813 1991-05-20

Publications (1)

Publication Number Publication Date
EP0586553A1 true EP0586553A1 (fr) 1994-03-16

Family

ID=24822712

Family Applications (1)

Application Number Title Priority Date Filing Date
EP92912819A Withdrawn EP0586553A1 (fr) 1991-05-20 1992-03-11 Derives de carboxamido-(3,2n)-2-aminotetralinecarbocyclique

Country Status (6)

Country Link
EP (1) EP0586553A1 (fr)
JP (1) JPH06507906A (fr)
AU (1) AU2153592A (fr)
MX (1) MX9202291A (fr)
TW (1) TW200460B (fr)
WO (1) WO1992021654A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9612153D0 (en) * 1996-06-11 1996-08-14 Smithkline Beecham Plc Compounds
DE19834714A1 (de) * 1998-07-31 2000-02-03 Boehringer Ingelheim Pharma Neue 2,3,3a,4,9,9a-Hexahydro-8-hydroxy-1H-ben[f]indole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH22782A (en) * 1983-02-01 1988-12-12 Sandoz Ltd Novel pharmaceutical active 1,2,3,4,4a,5,10,10a octahydrobenzo(g)quinoline derivatives
DE3719924A1 (de) * 1986-12-22 1988-06-30 Bayer Ag 8-substituierte 2-aminotetraline
AU648032B2 (en) * 1989-07-13 1994-04-14 Pharmacia & Upjohn Company (1,2N) and (3,2N)-carbocyclic-2-amino tetralin derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9221654A2 *

Also Published As

Publication number Publication date
MX9202291A (es) 1992-11-01
AU2153592A (en) 1993-01-08
WO1992021654A2 (fr) 1992-12-10
TW200460B (fr) 1993-02-21
WO1992021654A3 (fr) 1993-01-07
JPH06507906A (ja) 1994-09-08

Similar Documents

Publication Publication Date Title
McDermed et al. Synthesis and dopaminergic activity of (+-)-,(+)-, and (-)-2-dipropylamino-5-hydroxy-1, 2, 3, 4-tetrahydronaphthalene
US4564628A (en) Substituted 2-aminotetralins
FR2696453A1 (fr) Nouveaux arylalkyl(thio)amides, leur procédé de préparation, et les compositions pharmaceutiques qui les contiennent.
KR19990028757A (ko) 벤조[ｇ]퀴놀린 유도체
KR100207876B1 (ko) 치료학적으로 유용한 2-아미노테트랄린 유도체
KR900003883B1 (ko) 3,4-디하이드로-2h-[ 1 ]-(벤조피란 및 벤조 티오피란)-3-아민 및 이의 제조방법
JP2818692B2 (ja) 新規な８―置換―２―アミノテトラリン類
JPH11263761A (ja) 新規なナフタレン化合物、それらの製造方法、及びそれらを含む医薬組成物
EP0617618A1 (fr) Aryltriflates et composes associes
AU1888501A (en) Novel substituted tricyclic compounds
US5486611A (en) Carboxamido-(1,2N)-carbocyclic-2-aminotetralin derivatives
US5491236A (en) (1,2N) and (3,2N)-carbocyclic-2-amino tetralin derivatives
EP0998471B1 (fr) Composes heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US5712312A (en) Tricyclic amides
EP0586553A1 (fr) Derives de carboxamido-(3,2n)-2-aminotetralinecarbocyclique
US5306830A (en) Substituted 3-amino chromans
CA2047236C (fr) Derives de substitution de 3-aminochromanes
US5071858A (en) Antipsychotic benzothiopyranylamines
AU2746902A (en) New indenoindolone compounds, a process for their preparation and pharmaceutical compositions containing them
US5641785A (en) Oxazoloquinolinone derivatives, their preparation and their therapeutic application as inhibitors of monoamine oxidase
WO1994026703A1 (fr) Nouveaux esters de sulphone a substitution en 5,6,7 et 8 de 2-aminotetralines n-monosubstituees a action centrale et structures apparentees
IE63769B1 (en) Aryloxypropanolaminotetralins a process for their preparation and pharmaceutical compositions containing them
US20030069274A1 (en) Pharmaceutically active compounds and methods of use
HU185476B (en) Process for producing benzo-bracket-4,5,-aracket closed-pyrano-bracket-2,3-c-bracket closed-pyrrole derivatives and pharmaceutical compostions containing them as active agents
CA2118920A1 (fr) Derives benzo-isoquinoline et leurs analogues, et leur utilisation therapeutique

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19931214

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

17Q First examination report despatched

Effective date: 19940524

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19950411